Patents by Inventor Philippe Bonniaud

Philippe Bonniaud has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of pulmonary and pleural fibrosis using HSP27 inhibitors
    Patent number: 9326993
    Abstract: Reduction of HSP27 expression is in beneficial in the treatment of pleural and pulmonary fibrosis and in particular subpleural fibrosis and IPF. Pharmaceutical compositions for this purpose contain an inhibitor of HSP27 and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: December 17, 2014
    Date of Patent: May 3, 2016
    Assignee: ONCOGENEX TECHNOLOGIES INC.
    Inventors: Philippe Bonniaud, Carmen Garrido, Guillaume Wettstein
  • Treatment of Pulmonary and Pleural Fibrosis Using HSP27 Inhibitors
    Publication number: 20150126584
    Abstract: Reduction of HSP27 expression is in beneficial in the treatment of pleural and pulmonary fibrosis and in particular subpleural fibrosis and IPF. Pharmaceutical compositions for this purpose contain an inhibitor of HSP27 and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: December 17, 2014
    Publication date: May 7, 2015
    Inventors: Philippe Bonniaud, Carmen Garrido, Guillaume Wettstein
  • Treatment of pulmonary and pleural fibrosis using HSP27 inhibitors
    Patent number: 8987223
    Abstract: Reduction of HSP27 expression is in beneficial in the treatment of pleural and pulmonary fibrosis and in particular subpleural fibrosis and IPF. Pharmaceutical compositions for this purpose contain an inhibitor of HSP27 and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: May 14, 2012
    Date of Patent: March 24, 2015
    Assignee: Oncogenex Technologies Inc.
    Inventors: Philippe Bonniaud, Carmen Garrido, Guillaume Wettstein
  • Treatment of Pulmonary and Pleural Fibrosis Using HSP27 Inhibitors
    Publication number: 20120294846
    Abstract: Reduction of HSP27 expression is in beneficial in the treatment of pleural and pulmonary fibrosis and in particular subpleural fibrosis and IPF. Pharmaceutical compositions for this purpose contain an inhibitor of HSP27 and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: May 14, 2012
    Publication date: November 22, 2012
    Applicant: ONCOGENEX TECHNOLOGIES INC.
    Inventors: Philippe Bonniaud, Carmen Garrido, Guillaume Wettstein